Nevertheless, circulating levels of ACE2 in serum of type 2 diabetes mellitus (DM) patients are rather low (4), so the effect of RAAS inhibitors in combination with COVID-19 and DM remains unknown. The gene discussed is ACE2; the disease is COVID-19.